Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ViiV Healthcare
With
Pfizer
The study was terminated on October 8, 2013 following a preliminary review of the Week 48 primary efficacy data by the study's external independent Data Monitoring Committee (DMC). The DMC assessed the data as demonstrating significant differences between the treatment arms in virologic responses and failures. The DMC recommended and the Sponsor concurred that the study be terminated because of the inferior efficacy of the Maraviroc arm as compared to the comparator arm (Emtricitabine/Tenofovir).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Plasma HIV-1 RNA equal to or greater than 1,000 copies/mL measured at the Screening Visit.
CD4 count equal to or greater than 100 cells/mm3 at Screening.
Have only R5 HIV 1 at Screening as verified by a randomized tropism assay.
You may not be if
Prior treatment with any other HIV antiretroviral therapy for more than 14 days at any time.
Any evidence of genotypic/phenotypic resistance to darunavir, tenofovir, and emtricitabine.
CXCR4 using virus detected using randomized tropism determination or repeated failure to obtain an interpretable tropism result.
Clareo Health | Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
